SKILLMAN, N.J. September 27, 2024 — Kenvue Inc. (the Company or Kenvue) will present new data demonstrating effective sleep and skin moisturization strategies for babies during the American Academy of Pediatrics (AAP) National Conference & Exhibition, set for September 27 through October 1, 2024, in Orlando, Florida.
In addition to findings supporting bedtime and naptime routines, the data also confirms itchy skin interrupts sleep in babies and toddlers. The Company will also share research demonstrating the effectiveness of its Aveeno®[1] skin-moisturizing formulations for infants, such as a clinical trial data highlighting Aveeno® Baby Healthy Start Newborn Balm’s superiority in moisturization over 48-hours compared to CeraVe® Baby Body Lotion.
“Our findings show that everyday care strategies, including bedtime routines and emollient-rich oat-containing skin balms, have the power to improve infant sleep quality,” said Catherine Mack[2], Ph.D., Head of Baby Translational Science at Kenvue. “By recommending these measures, pediatricians can support the health and well-being of everyone in a household. We are looking forward to joining pediatric experts from across the globe at AAP to share these latest insights.”
Exploring the Data
Kenvue will present the following findings generated by research teams composed of both academic experts and scientists:
· Sleep routines and parent perceptions in infants; Jodi A. Mindell, Ph.D., et al
In tracking bedtime and naptime routines over the first eight months of life, most parents surveyed said it was easy to institute bedtime customs, such as cuddling and bathing, that helped their babies fall and stay asleep and promoted bonding. Naptime routines were less common and more associated with bonding than with fostering sleep. Parents had positive perceptions of these practices, and the authors concluded that pediatricians should recommend sleep routines to all families.
· Sleep problems and allergic skin conditions in infants and toddlers; Erin S. Leichman, Ph.D., NCSP, DBSM, et al
Atopic dermatitis, or eczema, has been associated with sleep difficulties, and to explore that dynamic in early life, researchers asked parents to track sleep quality in infants with and without allergic skin conditions. Parents reported a higher rate of sleep problems in children who had itchy skin but not necessarily a diagnosis of eczema. Researchers concluded that pediatricians should assess for itchy skin and its associated sleep problems, even in babies who do not meet the criteria for atopic dermatitis.
Jodi Mindell, Ph.D. and a psychologist at the Children’s Hospital of Philadelphia, will be presenting two abstracts on Sunday, September 29 from 10:00am-12:00pm:
· Sleep Problems and Allergic Skin Conditions in Infants and Toddlers
· Sleep Routines and Parent Perceptions in InfantsBoth are part of Session (H30033) Section on Integrative Medicine in the Hyatt Regency Ballroom
Gabrielle Kosmoski[3], R&D Manager, Claims and Clinical Strategy at Kenvue will share a new comparative study on the efficacy of Aveeno® Baby Healthy Start Newborn Balm. This data shows immediate improvement in skin hydration, dryness and roughness compared to leading competitors, and will be presented in the Kenvue Scientific Theater, within booth #800 on Saturday, September 28 at 2:50pm.
· Moisturization Clinical Share-out; a Single-Center, Randomized Clinical Trial to Assess the Moisturization Efficacy of Topically Applied Investigational Products over the Course of 48 hours After a Single Application Among Adult Subjects with Dry Skin
In this randomized, evaluator-blinded study, investigators assessed a variety of over-the-counter moisturizers formulated for babies by observing their effects on the forearms of adults with dry skin. They found that Aveeno® Baby Healthy Start Newborn Balm was more moisturizing than either CeraVe® Baby Gentle Moisturizing Body Lotion or Cetaphil® Baby Soothe & Protect Cream and better than the CeraVe® formula at improving skin’s barrier function.
“These compelling results affirm Aveeno® Baby Healthy Start Newborn Balm’s superior performance in providing lasting hydration and strengthening the skin barrier,” said Gabrielle Kosmoski, R&D Manager, Claims and Clinical Strategy at Kenvue. “Aveeno® Baby Healthy Start Newborn Balm’s, with triple oat complex, is inspired by the vernix, leaving a nourishing layer that cares for the newborn’s skin. Our research demonstrates Aveeno® Baby Healthy Start Newborn Balm’ is safe to use on a baby’s first day of life. We will continue to demonstrate our commitment to quality and effectiveness ensures that parents can trust our products to care for their baby’s delicate skin.”
Other presentations held in the Kenvue Scientific Theater include:
· Early Emollient Use from Infancy
· Pediatric Skin Conditions in Skin of Color and the Role of Culture in Newborn Skincare Practices
· The Power of Oat in Newborns and Infants and,
· Kenvue’s Golden Standards on Formulation and Fragrance
To learn more about any of these studies, presentations, or to schedule interviews with their authors, please contact Kenvue R&D media relations.
[1], 2, 3 Aveeno® is a registered brand of Johnson & Johnson Consumer Inc., a subsidiary of Kenvue Inc. Catherine Mack and Gabrielle Kosmoski are employees of Johnson & Johnson Consumer Inc., a subsidiary of Kenvue Inc.